Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study Aims: Both morphological and molecular approaches have highlighted the biological and prognostic importance of the tumour microenvironment in colorectal cancer (CRC). Despite this, microscopic assessment of the tumour microenvironment has not been adopted into routine practice. The study aim was to identify those tumour microenvironmental features that are most likely to provide prognostic information and be feasible to use in routine pathology reporting practice. Methods and results: On the basis of existing evidence, we selected specific morphological features relating to peritumoral inflammatory and stromal responses, agreed criteria for scoring, and assessed these in representative haematoxylin and eosin (H&E)-stained whole tumour sections from a population-based cohort of 445 stage II/III colon cancer cases. Moderate/severe peritumoral diffuse lymphoid inflammation and Crohn's disease-like reaction were associated with significantly reduced risks of CRC-specific death [adjusted hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.31-0.76, and HR 0.60, 95% CI 0.42-0.84, respectively]. The presence of >50% tumour stromal percentage, as assessed by global evaluation of tumour area, was associated with a significantly increased risk of CRC-specific death (HR 1.60 95% CI 1.06-2.41). A composite 'fibroinflammatory score' (0-3), combining dichotomized scores of these three features, showed a highly significant association with survival outcomes. Those with a score of ≥2 had an almost 2.5-fold increased risk of CRC-specific death (HR 2.44, 95% CI 1.56-3.81) as compared with those scoring zero. These associations were stronger in microsatellite instability (MSI)-high tumours, potentially identifying a subset of MSI-high colon cancers that lack characteristic morphological features and have an associated worse prognosis. Conclusions: In summary, reporting on H&E staining of selected microscopic features of the tumour microenvironment, independently or in combination, offers valuable prognostic information in stage II/III colon cancer, and may allow morphological correlation with developing molecular classifications of prognostic and predictive relevance.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer death in developed countries, and is estimated to be increasing in incidence worldwide, particularly in low/middle-income countries.
1,2 Evaluation of tumour morphology has been the mainstay of prognostication for decades, guiding management through assessment of tumour grade, stage, and other histological features of proven clinical significance. Recently, there has been a major focus on transcription-based molecular classification of CRC and the prognostic significance of subtypes. [3] [4] [5] However, given the limited availability and current high cost of routine molecular subtyping of CRC, this is likely to remain a future goal for now.
Both morphological studies and recent molecular classifications of CRC have highlighted the importance of the tumour microenvironment, reinvigorating interest in the 'seed and soil' hypothesis of colorectal carcinogenesis. 6 The first CRC consensus molecular subtype (CMS) classification, which combined gene expression data from >4000 patients, includes 'immune' (CMS1) and 'mesenchymal' (CMS4) subtypes. 5 The defining contribution of the tumour microenvironment to the overall expression profile traits associated with each subtype has since been highlighted, in addition to the potential for misclassification resulting from intratumoral heterogeneity in localized regions of the primary tumour. [7] [8] [9] Many prior morphological studies, some decades old, have examined selected features of the tumour microenvironment. Previous assessments by routine microscopy of haematoxylin and eosin (H&E)-stained sections demonstrated the prognostic significance of a variety of features related mainly to peritumoral inflammation and stromal reaction. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] However, there has been limited validation of results in larger studies. Lack of standardization of methods for assessment and unconvincing interobserver reproducibility for some parameters have prevented uptake into routine reporting practice.
There is an ongoing need for more reliable and reproducible prognostic morphological features in CRC, especially in stage II disease, given the well-documented divergent clinical outcomes. [29] [30] [31] In addition, there is a desire to maximize all available information from routine pathological assessment of CRC resection specimens. To this end, we have chosen from the existing literature the most promising tumour microenvironmental features, related to host immune and stromal proliferative responses. We have evaluated these on H&E-stained whole tumour sections derived from a large population-based cohort of stage II and stage III colon cancer cases. Interobserver and intraobserver reproducibility were rigorously assessed. The overall study aim was to identify those tumour microenvironmental features that are most likely to provide prognostic information and be feasible to use in routine pathology reporting practice.
Materials and methods

C A S E I D E N T I F I C A T I O N
Stage II and III colon cancer patients (ICD code C.18, n = 1862) diagnosed in Northern Ireland from 2004 and up to 2008 were identified from the Northern Ireland Cancer Registry. Rectal and rectosigmoid junction cancers were excluded because of the potential for neoadjuvant therapy to alter tumour morphology. Exclusions were applied to retain only patients with a single, primary colon adenocarcinoma that had been treated by surgical resection (n = 1539). A detailed clinical case note review was conducted, to verify diagnosis and stage, and to extract clinical information, including the use of adjuvant chemotherapy and outcome. Following this review,113 cases were excluded, mainly on the basis of inaccurate staging. Of the remaining 1426 patients, 740 patients (52%) were diagnosed within the jurisdiction of the Northern Ireland Biobank, allowing retrieval of glass slides for pathology review. Slides from 661 (89%) of these cases were located and, within the study timeframe, 473 consecutive cases underwent slide review and evaluation in this study. These cases were representative of the overall 661 cases with available slides, except that they were more likely to be diagnosed in earlier years of the cohort, owing to the consecutive nature of slide review (data not shown). All patients were followed up for occurrence and cause of death via linkage to the Northern Ireland Registrar General's Office up to 31 December 2013. Patients were recorded as having a CRC-specific death if any cause of death was listed as ICD codes C18, C19, C20, and/or C26. Ethical approval for resection specimen retrieval was received from the Northern Ireland Biobank (REC:11/NI/ 0013, project NIB13-0069).
M O R P H O L O G Y R E V I E W P R O C E S S
Generation of the NIB13-0069 study resource included review of all glass slides from the relevant surgical resection specimens to select the two most representative tumour blocks from each case, at least one of which represented the advancing edge/invasive margin of the tumour. Slide review for this study was based on further evaluation of these two representative H&E-stained slides for each case. All cases were reviewed for the selected morphological features by a pathology fellow with an interest in gastrointestinal pathology (S.O.H.). Prior to the study review, random colonic adenocarcinoma cases (n = 10) were discussed at two multi-header microscopy conference sessions with three other pathologists, two consultant gastrointestinal pathologists (M.B.L. and P.J.K.), and one trainee pathologist (S.I.). These four constituted the study pathologist group. The purpose of these sessions was to select suitable morphological features of potential relevance to the study, based on existing evidence, and to decide what criteria to apply to define and score these parameters, applicable to routine practice.
After agreement had been reached on study parameters and criteria for scoring, a random set of 36 cases (representing 5% of the overall 661 cases eligible for inclusion in the study) was chosen for blinded interobserver and intraobserver analysis, the latter following a 6-week washout period. These analyses involved all observers evaluating both available slides for each case, without any annotations or other indicators of the regions of interest chosen by others.
In addition to the chosen microenvironmental features, the study also assessed tumour typing/subtyping and differentiation, based on World Health Organization (WHO) 2010 criteria. 32 Other pathology data items, including nodal status and the presence or absence of extramural venous invasion, were recorded from pathology reports. The agreed approach and scoring system applied to the study microenvironmental features evaluated are described below and summarized in Table 1 .
Peritumoral lymphoid inflammation
The Klintrup-Makinen system, based on H&E assessment of overall inflammatory response (all inflammatory cell types) at the advancing tumour edge, is widely validated and considered to be reproducible and more valuable than the simpler, preceding Jass scoring system. 10, 13, 17, 21 However, the available evidence suggests that, within the inflammatory infiltrates, it is the lymphoid population, assessed on routine microscopy or on immunohistochemistry, that is of most prognostic value. 12, 13, 15, 17, 24 Some studies have indicated that immunohistochemical evaluation of specific subsets of lymphoid cell populations currently adds little prognostic value over H&E assessment. 12, 13, 15, 33 A modification of the Klintrup-Makinen scoring system was therefore chosen, assessing lymphoid cell infiltrates only, within stromal tissue along the invasive tumour front, and ignoring other inflammatory cell populations. Lymphoid infiltrates were scored as: absent/mild, featuring scattered lymphocytes only (0); moderate, with a band-like mantle infiltrate and at least focal gland destruction (1); and severe, showing a cup-like lymphoid reaction and marked gland destruction (2) . This scoring is illustrated in Figure 1 .
Crohn's disease-like reaction In addition to peritumoral lymphoid reaction at the advancing edge, the so-called Crohn's disease-like reaction (CLR) in peritumoral tissue was assessed. In contrast to peritumoral diffuse lymphoid inflammation, Crohn's disease-like lymphoid aggregates are composed predominantly of B cells rather than T cells. 12 These organized lymphoid structures constitute an essential component of adaptive immunity. 34 As compared with peritumoral T-cell reaction, relatively little evidence exists for the prognostic value of CLR in CRC. 12, 23, 35 Scoring was based on the Graham and Appelman criteria, with three categories: none or a maximum of one peritumoral lymphoid aggregate per section (0); occasional lymphoid aggregates with no or rare germinal centres (1); and numerous lymphoid aggregates, some with germinal centres (2) . 23 This scoring is illustrated in Figure 2 .
Tumour stromal percentage
Multiple studies have reported intratumoral stroma/ epithelium ratio or tumour stromal percentage to be prognostic in stage I-III CRC, as assessed with different methodologies. 11, 20, 22, 26 Mesker et al. simply applied a visual estimation of percentage epithelium and stroma on the whole available tumour area. 20 Two more recent studies employed a focal assessment within a single low-power field from the advancing tumour edge. 22, 26 Both of these methods were applied in this study. The global assessment categorized tumours as >50% or <50% tumour stromal percentage. The focal method involved choosing the most invasive region of the tumour at scanning magnification, and then, at 910 objective, selecting a field from this region in which tumour epithelium was present at the four cardinal points of the field. A visual estimate of tumour stromal percentage by area was then made from within this single 910 field, categorized as <50% or >50%. In both the global and focal assessments, empty glandular luminal space, luminal necrosis, extracellular mucin and native smooth muscle tissue were excluded from the visual assessment of tumour stromal percentage. Examples of tumours with high and low stromal percentages are shown in Figure 3 .
M I C R O S A T E L L I T E I N S T A B I L I T Y ( M S I ) A N A L Y S I S
DNA was extracted according to the manufacturer's instructions from five 5-lm sections of representative tumour blocks with the Maxwell 16 Instrument (Promega, Southampton, UK) and Promega DNA extraction kit, after enrichment for tumour by slide annotation and macrodissection. Quantification of DNA was performed with an absorbance method by use of the NanoDrop 2000c spectrophotometer (Thermo Scientific, Wilmington, DE, USA). MSI analysis was performed within the Northern Ireland Molecular Pathology Laboratory, according to the manufacturer's instructions, with the MSI Analysis System, version 1.2 kit (Promega) for five mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24, and MONO-27). Polymerase chain reaction products were separated by capillary electrophoresis with an ABI 3500 Genetic Analyzer (Fisher Scientific UK, Loughborough, UK). The output data were 
S T A T I S T I C A L A N A L Y S I S
Of the 473 cases reviewed in this study, patients with a known familial CRC predisposition syndrome (n = 5) or who died within the first 30 days of follow-up (n = 23) were excluded, leaving 445 colon cancer patients in our analytical dataset. Kappa values were generated to compare interobserver and intraobserver variability in scoring morphological features. Fleiss's cutoffs indicate poor, fair to good and excellent agreement for kappa scores of <0.4, 0.4-0.75, and >0.75, respectively.
Cox proportional hazards analysis was applied to generate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall and CRC-specific survival according to morphological features. Patients were followed up from their date of diagnosis as per cancer registry records until their date of death or 31 December 2013. Survival analysis was conducted both prior to and after adjustment for potential confounders: age, sex, family history of CRC, Eastern Cooperative Oncology Group (ECOG) performance status, tumour stage, tumour grade, extramural venous invasion, and MSI status. Morphological tumour subtype was tested as a confounder, but did not alter the results, and was therefore not included in the final model. Overall survival analysis was also adjusted for Charlson comorbidity score.
All morphological features were then entered into a regression model, and any that had a P-value of <0.25 were considered to be associated with CRC-specific death-this group comprised peritumoral lymphoid inflammation, CLR, and global tumour stromal percentage assessment. Each of these features was then dichotomized so that individuals were assigned a score of 0 or 1 for each, whereby 1 = absent/mild peritumoral lymphoid inflammation, absent/mild CLR, and >50% global tumour stromal percentage (on the basis that these factors were associated with poorer outcomes on individual analysis). Patients could therefore have a combined morphological fibroinflammatory score range of 0-3 (Table 1) .
Stratified analysis for individual morphological features, and combined score, was conducted according to MSI status, chemotherapy receipt, and tumour stage. Likelihood ratio tests were applied to formally assess the interaction between these features and CRC survival. All statistical analysis was conducted with STATA version 11.2 (StataCorp, College Station, TX, USA).
Results
C H A R A C T E R I S T I C S O F C R C P A T I E N T S A N D T U M O U R S
As shown in Table 2 , over a mean 5.5 years (range 0.1-10 years) of follow-up, 206 colon cancer patients had died, of whom 144 died from a CRC-specific cause. Patients who died from CRC were more likely to be older and have higher ECOG scores (reflecting overall poorer health) and were less likely to receive adjuvant chemotherapy than patients still alive at the end of follow-up. No differences in sex distribution or family history of CRC were observed. In terms of tumour biology, patients who died from CRC were more likely to have higher-stage disease, nodal involvement, and extramural venous invasion, and less likely to have MSI-H tumours, than patients who survived, whereas no differences were seen by WHO tumour type. Similar differences were noted for all-cause deaths. (Table 3 ). Peritumoral lymphoid inflammation showed excellent intraobserver agreement but only poor to fair interobserver agreement. Interobserver and intraobserver agreement on assessment of tumour stromal percentage with the focal method were only good at best.
The two measures of inflammation assessed have some overlap, in that they both looked at peritumoral lymphoid reactions. Within the overall patient cohort (of 445), 277 (62.2%) were scored as 1 or 2 for both peritumoral lymphoid inflammation and CLR, whereas 38 (8.5%) were scored as 0 for both.
Approximately one-quarter of patients (115, 25.8%) scored 1 or 2 for peritumoral lymphoid inflammation but 0 for CLR, whereas 15 (3.4%) scored 1 or 2 for CLR but 0 for peritumoral lymphoid inflammation. These proportions were similar regardless of MSI status (data not shown).
As shown in Table 4 , the presence of moderate/ severe peritumoral diffuse lymphoid inflammation and/or CLR was associated with a significant 40-52% reduced risk of CRC-specific death (adjusted HR 0.48, 95% CI 0.31-0.76, and HR 0.60, 95% CI 0.42-0.84, respectively). These associations maintained significance, but were attenuated to 36-37% reduced risks of death from any cause, suggesting that this good prognostic influence is driven by a CRC-specific effect. CRC, colorectal cancer; ECOG status, Eastern Cooperative Oncology Group performance status of cancer patients' general wellbeing and activities of daily life (0-1, fully active or restricted strenuous activity but able to carry out light activities; 2, ambulatory and able to selfcare, but unable to carry out work activities; 3-4, limited or no self-care, or bedbound); IQR, interquartile range; MSI, microsatellite instability; NOS, not otherwise specified. *All tumours were coded by cancer registry as adenocarcinoma. Following slide review in this study, specific types/subtypes identified other than adenocarcinoma, NOS, comprised mucinous adenocarcinoma (n = 29), medullary carcinoma (n = 3), and signet ring cell adenocarcinoma (n = 1).
The presence of >50% tumour stromal percentage, assessed globally, was associated with an increased risk of CRC-specific death (HR 1.60, 95% CI 1.06-2.41) and death from any cause (HR 1.52, 95% CI 1.07-2.16). These results were slightly attenuated for CRC-specific survival, but remained significant for overall survival after adjustment for other prognostic confounders (Table 4) . Tumour stromal percentage assessed focally was not associated with survival outcomes in this cohort.
C O M B I N E D M O R P H O L O G I C A L ' F I B R O I N F L A M M A T O R Y ' S C O R E A N D S U R V I V A L
The composite score based on dichotomized scores of three features (peritumoral lymphoid inflammation, CLR, and tumour stromal percentage) revealed a highly significant association when this score was analysed in relation to survival outcomes, even after adjustment for known confounders, including differentiation (Table 5 ; Figure 4 ). Patients with a score of 1 had a 53% increase in the hazard for CRC-specific death (HR 1.53, 95% CI 1.02-2.28), and those with a score of ≥2 had an almost 2.5-fold increased risk of CRC-specific death (HR 2.44, 95% CI 1.56-3.81), as compared with those scoring zero. Similar results were seen for all-cause mortality. Figure 5 illustrates similar directions of prognostic influence of the morphological features in both MSI status groups, although the magnitude of associations was considerably stronger in the MSI-H group. Patients with a fibroinflammatory score of 2 or 3, in comparison with those having a score of 0, had a 66% increased risk of CRC-specific death in the non-MSI-H group, as compared with a six-fold increased risk of CRC-specific death in the MSI-H group, although the latter is based on a very small number of patients (eight patients had MSI-H tumours with a fibroinflammatory score of 2 or 3, and seven of these patients died during the follow-up period). Significant interactions were observed between CRC-specific survival, MSI status and peritumoral inflammatory infiltrate (P = 0.002), and the overall fibroinflammatory score (P = 0.01).
S U B G R O U P A N A L Y S I S B Y M S I S T A T U S , C H E M O T H E R A P Y U S E , A N D T U M O U R S T A G E
Subgroup analysis by adjuvant chemotherapy receipt and tumour stage gave largely similar results to those seen in the overall cohort of CRC patients, although the magnitude of associations for inflammatory features was slightly stronger in stage III than in stage II patients (Table S1 ).
Discussion
The results from this large population-based cohort of stage II and III colon cancer patients indicate that three tumour microenvironmental features that are not currently reported in routine practice-peritumoral lymphoid infiltrate, CLR, and global assessment of tumour stromal percentage-are predictive of survival outcomes. These associations were evident when we took into consideration other established prognostic factors, such as tumour grade, stage, extramural venous invasion and MSI status, and patient demographics. With some caveats, assessment of these features has acceptable interobserver and intraobserver variation, suggesting that their introduction into routine clinical practice is feasible.
Despite significant progress in the molecular understanding of colorectal carcinogenesis, routine pathology reporting remains largely based on microscopic CI, confidence interval; HR, hazard ratio. *Combined score based on peritumoral inflammation (1 point if score 0 or 1), Crohn's disease-like reaction (1 point if score 0 or 1) and global tumour stromal percentage (1 point if >50%) to give a maximum combined fibroinflammatory index score of 3. Very few patients had a score of 3; therefore, this was combined with a score of 2 for statistical analysis. tumour assessment. Furthermore, reporting is focused almost exclusively on the epithelial tumour component, e.g. in staging and grading, and the tumour microenvironment is largely ignored. 36, 37 This is despite numerous morphological studies demonstrating prognostic significance of selected tumour microenvironmental features. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Broadly, these have been related either to peritumoral inflammatory response or to the intratumoral stromal component.
Peritumoral inflammation in CRC has been the subject of a large number of studies, both morphological and immunohistochemical, and a proposal has recently been advanced to report an Immunoscore for all CRC cases, applying immunohistochemistry and digital image analysis for scoring. 24 The presence of a significant peritumoral inflammatory infiltrate has assumed increased potential relevance recently for therapy-related decisions, with the advent of immune-based therapies, including checkpoint CTLA-4, PD-1 and PDL-1 inhibitors such as ipilimumab, which are currently being investigated in trials in colorectal and other cancers. 38 For example, we recently highlighted the presence of a good prognostic group in stage III CRC defined by high PD-L1 gene expression within the peritumoral immune cell infiltrate. 39 Routine application of multiple biomarkers by immunohistochemistry and digital image analysis for scoring remain unfeasible in routine reporting practice, however, particularly within low/middle-income countries, where the CRC incidence is rising most, so more consideration of routine H&E assessment is required. Regarding peritumoral inflammatory composition, the lymphoid component appears to offer most prognostic information, beyond the overall peritumoral inflammatory assessment favoured by Klintrup and Makinen, or other selected inflammatory cell populations, so peritumoral lymphoid inflammation was the chosen parameter in this study. Although interobserver variation in assessment was only poor to fair, post-study discussion by the four study pathologists suggested that this was, in part, related to the handling of certain inflammatory subpopulations, e.g. plasma cells. This highlights the importance of meticulous attention to standardization of assessment criteria and agreement of definitions. Intraobserver variation was excellent, and previous studies have also indicated good reproducibility for assessment of peritumoral inflammatory cell populations on H&E examination. 16, 21 Nevertheless, the reproducibility of such assessments is of paramount importance and requires rigorous evaluation in all such morphological studies and further careful consideration prior to incorporation of such assessments into routine practice. Whether evaluation of specific peritumoral inflammatory cell populations is preferably performed by H&E examination or by immunohistochemistry in addition requires consideration of resources and prognostic or predictive clinical application.
Both peritumoral lymphoid inflammation and CLR showed protective prognostic effects in this study, of similar magnitudes. This supports numerous previous studies of peritumoral diffuse inflammation, based on morphological and immunohistochemical assessments. 12, 13, 15, 17, 24 Less literature exists on the prognostic benefit of CLR in CRC, although one study, by Graham and Appelman, dates from 1990. 23 A recent, large study of CRC stages I-IV reported a prognostic value of peritumoral lymphoid aggregates that was independent of stage and of peritumoral inflammatory assessment (assessed by use of the Klintrup-Makinen score). 13 There was considerable overlap in scoring patterns for peritumoral lymphoid inflammation and CLR. Of the~30% of patients in the cohort with differential scoring for these two inflammatory parameters, most scored 1 or 2 for peritumoral inflammation and 0 for CLR. A smaller proportion of patients (3.4%, n = 15) conversely scored 1 or 2 for CLR and 0 for peritumoral lymphoid inflammation. Importantly, in the present study, the reproducibility of CLR assessments was significantly better than that of peritumoral lymphoid inflammation. Thus, we consider both to be worthy of independent assessment, in accordance with the study by Klintrup et al., which concluded that CLR and inflammatory reaction at the advancing tumour edge do not represent a phenotypic variation of the same immune defence mechanism, but are, rather, independent and each of prognostic value. We adopted two approaches to assess tumour stromal percentage, one global and one focal, both of which have been reported previously to have prognostic relevance in CRC. 20, 22, 26 West et al. used a more precise morphometric method, and obtained similar findings, but this approach is considered to be too timeconsuming for routine use, taking, on average, 20 min per case in that study. 11 We found the global assessment of >50% tumour stromal percentage, but not the focal assessment, to be associated with significantly increased hazard for a CRC-specific cause of death. Both intraobserver and interobserver reproducibility of global stromal assessment were also much better than those of focal stromal assessment. This contradicts findings from two previous studies, both describing excellent reproducibility of the focal method. 22, 26 However, whereas our study allowed each pathologist to select an independent study field based on their own assessment of the requirements, neither of these articles describes in sufficient detail how interobserver variability was assessed, specifically how independent was the selection of study fields between observers. On post-study evaluation, we found selection of 'the most invasive field', as required by the Huijbers et al. method, varied considerably between study participants, even when they were examining only two slides per case, and this had a profound influence on reproducibility. This can only be expected to be a greater problem in everyday reporting practice, with more tumour slides to evaluate per case. Global assessment, considering all available tumour tissue area, as originally proposed by Mesker et al. in a smaller study, appears to be a more reproducible and valuable parameter. 20 By combining dichotomized scores from the three tumour microenvironmental features found to be of prognostic value, a 'fibroinflammatory score' (0-3) was derived for each case, and was found to better predict prognosis than any of the individual features, with a highly significant association being evident. One previous study assessed similar tumour microenvironmental features in a large CRC cohort, and described a tumour stromal prognostic influence in the context of local and systemic host responses, including peritumoral inflammation, but, to our knowledge, this is the first study to combine these features to derive a tumour microenvironmental score of local stromal and inflammatory response. 26 The potential for confounding interobserver variation in assessments of individual features can be reduced by using the proposed combined score.
This proposed addition to routine morphological assessment of CRC correlates well with renewed interest in the tumour microenvironment, and the concept of distinguishing features of the tumour 'seed' (malignant epithelium) from the tumour 'soil' (immune system and stroma). 6 This impacts on the proposed transcriptional profiling of CRC, with CMS subtypes including an 'immune' subtype (CMS1), characterized largely by MSI and related clinicopathological features, including an excellent prognosis, and a 'mesenchymal' subtype (CMS4), characterized by microsatellite stability, epithelial-mesenchymal transition, and a poor prognosis. 5 Subanalysis by MSI status in our cohort suggests that, within the group of MSI-H colon cancers, there exists a subgroup that lacks the characteristic morphological features (scoring 2 or 3 for fibroinflammatory score), and this group has a worse prognosis than MSI-H tumours with classic morphology. Therefore, morphological assessment of the tumour microenvironment adds value beyond MSI status to prognostication in the MSI-H group in particular. This is in agreement with our findings from a transcription-based study, in which some MSI-H tumours appeared to have a low immune infiltration signature, similarly to non-MSI-H tumours. 39 Additionally, these findings support a recent study indicating that tumour Immunoscore offers greater prognostic value than assessment of MSI status. 40 The strengths of this study include its populationrepresentative cohort of stage II and III colon cancer patients, relatively large overall study numbers, careful consideration of the reproducibility of assessments, feasibility for introduction into routine practice, and correlation of traditional morphological assessment with current molecular approaches to CRC subtyping. A study weakness is that restriction of tumour assessments to two slides per case, rather than examining all tumour slides, does not reflect real-life practice and may somewhat distort the data on reproducibility. Also, we have not examined rectal cancers in this study.
In summary, supporting previous studies, we have found that reporting of selected features of the tumour microenvironment in stage II-III colon cancer offers prognostic information. We consider peritumoral lymphoid inflammation at the advancing edge, CLR and tumour stromal percentage as the microenvironmental features that are likely to be most reproducibly assessed and to offer the most prognostic value. We therefore propose that assessment of these tumour microenvironmental parameters be introduced into routine reporting practice, at least until such time as adjunctive targeted immunohistochemistry panels and digital image analysis are more readily available.
